Akebia Therapeutics, Inc. (NASDAQ: AKBA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Akebia reported FY19 earnings yesterday. 4Q19 EPS was $(0.79) vs. Factset Consensus of $(0.47), and FY19 EPS was $(2.36) vs. FactSet Consensus of $(2.07). We do not see earnings as the most important value driver for Akebia at this stage. Importantly, the company remains on track to report Phase 3 data from vadadustat in 2Q20, and mid-2020. We expect investors will pay close attention to the data, including safety and efficacy compared to standard of care. We believe a result of non-inferiority would be positive for the shares, enabling FDA approval, and the potential to change the current standard of care.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit the company’s website at www.akebia.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.
